This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
Tip of the Month
Tip of the month - Selective Laser Trabeculoplasty (SLT) can be considered as the first treatment for newly diagnosed patients with ocular hypertension and mild to moderate primary open angle glaucoma
Selective Laser Trabeculoplasty (SLT) can be considered as the first treatment for newly diagnosed patients with ocular hypertension and mild to moderate primary open angle glaucoma

Publishing date: May 2019

Tip Editor: John Salmon
Tip reviewer: Roger Hitchings


The Science behind the Tip

The LiGHT trial compared two treatment pathways for treatment naïve ocular hypertension and mild to moderate glaucoma. 718 patients were randomised to either primary SLT (100 shots over 360 degrees) and later medications as required or primary medical treatment with no laser. After 3 years, 78% of eyes with SLT treatment were still controlled, achieving predetermined eye-specific Target IOPs without medication and with no sight-threatening complications of laser. Three quarters of these required only a single SLT treatment. Primary SLT was both clinically effective and more cost effective than primary medical therapy.

Contributor: Gus Gazzard, London




Reference

Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular
hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial
Gazzard G et al.
https://www.thelancet.com/journals/lancet/issue/vol393no10180/PIIS0140-
6736(19)X0016-1

https://www-sciencedirectcom.libproxy.ucl.ac.uk/search?authors=gazzard&pub=The%20Lancet&cid=271074&show=2
5&sortBy=relevance&years=2019&lastSelectedFacet=years




back to top